Altimmune Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ALT Nasdaq 2834 https://altimmune.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Altimmune Inc

Altimmune to Host Key Opinion Leader Call on ALT-801 for the Treatment of NASH - Nov 21st, 2019 1:00 pm
Altimmune Announces Third Quarter 2019 Financial Results and Provides a Business Update - Nov 13th, 2019 9:15 pm
If You Had Bought Altimmune (NASDAQ:ALT) Stock A Year Ago, You'd Be Sitting On A 48% Loss, Today - Nov 11th, 2019 10:43 am
Altimmune to Announce Third Quarter 2019 Financial Results on November 14 - Nov 6th, 2019 12:00 pm
Why the Facebook political-ads debate could be a windfall for legacy media - Nov 1st, 2019 6:41 pm
Altimmune to Participate in Upcoming Investor Conferences - Oct 10th, 2019 11:00 am
Altimmune Appoints M. Scott Harris, M.D. as Chief Medical Officer - Sep 9th, 2019 11:00 am
Altimmune Announces $3.7 Million in Additional BARDA Funding to Advance NasoShield™ Clinical Development - Aug 21st, 2019 11:00 am
Altimmune Announces Second Quarter 2019 Financial Results and Provides a Business Update - Aug 13th, 2019 8:15 pm
Altimmune to Announce Second Quarter 2019 Financial Results on August 14 - Aug 5th, 2019 11:00 am
Altimmune Announces Closing of Acquisition of Spitfire Pharma, Inc. - Jul 15th, 2019 11:00 am
Altimmune To Acquire Spitfire Pharma For $5M, Add NASH Drug To Portfolio - Jul 9th, 2019 12:48 pm
Altimmune Signs Definitive Agreement to Acquire Spitfire Pharma, Inc. Adding NASH Drug Candidate to Portfolio - Jul 9th, 2019 11:00 am
Altimmune Appoints Will Brown as Chief Financial Officer - Jun 12th, 2019 12:00 pm
Altimmune Announces Successful Pre-IND Meeting with FDA - Jun 10th, 2019 12:00 pm